301263 泰恩康
已收盘 05-24 15:00:00
资讯
新帖
简况
泰恩康最新公告:全资子公司获得枸橼酸西地那非口崩片药品注册证书
证券之星 · 05-21
泰恩康最新公告:全资子公司获得枸橼酸西地那非口崩片药品注册证书
泰恩康(301263.SZ)获得两项药品注册证书
智通财经 · 05-21
泰恩康(301263.SZ)获得两项药品注册证书
泰恩康(301263.SZ)拟10股派3元 于5月23日除权除息
智通财经 · 05-15
泰恩康(301263.SZ)拟10股派3元 于5月23日除权除息
泰恩康(301263.SZ):利多卡因丙胺卡因气雾剂药品注册临床试验获受理
智通财经 · 05-10
泰恩康(301263.SZ):利多卡因丙胺卡因气雾剂药品注册临床试验获受理
泰恩康最新公告:全资子公司利多卡因丙胺卡因气雾剂收到药品注册临床试验受理通知书
证券之星 · 05-10
泰恩康最新公告:全资子公司利多卡因丙胺卡因气雾剂收到药品注册临床试验受理通知书
华安证券:给予泰恩康买入评级
证券之星 · 05-08
华安证券:给予泰恩康买入评级
泰恩康4月30日现1笔大宗交易 成交金额4218万元
智能小浪 · 04-30
泰恩康4月30日现1笔大宗交易 成交金额4218万元
4月30日泰恩康现4218万元大宗交易
证券之星 · 04-30
4月30日泰恩康现4218万元大宗交易
泰恩康(301263.SZ):甲巯咪唑片境内生产药品注册上市许可申请获受理
智通财经 · 04-26
泰恩康(301263.SZ):甲巯咪唑片境内生产药品注册上市许可申请获受理
泰恩康上市次年营收净利齐降 医药代理板块贡献过半营收财报提示风险
中国网财经 · 04-26
泰恩康上市次年营收净利齐降 医药代理板块贡献过半营收财报提示风险
泰恩康:4月24日高管李挺增持股份合计5.55万股
证券之星 · 04-25
泰恩康:4月24日高管李挺增持股份合计5.55万股
泰恩康:4月23日高管李挺增持股份合计10.87万股
证券之星 · 04-24
泰恩康:4月23日高管李挺增持股份合计10.87万股
【机构调研记录】金元顺安基金调研贝达药业、泰恩康
证券之星 · 04-24
【机构调研记录】金元顺安基金调研贝达药业、泰恩康
【机构调研记录】湘财基金调研泰恩康
证券之星 · 04-24
【机构调研记录】湘财基金调研泰恩康
泰恩康(301263)2024年一季报简析:净利润减12.54%
证券之星 · 04-24
泰恩康(301263)2024年一季报简析:净利润减12.54%
泰恩康:泰信基金管理有限公司、兴业基金管理有限公司等多家机构于4月23日调研我司
证券之星 · 04-23
泰恩康:泰信基金管理有限公司、兴业基金管理有限公司等多家机构于4月23日调研我司
泰恩康(301263.SZ)董事李挺拟斥200万元至400万元实施增持
智通财经 · 04-23
泰恩康(301263.SZ)董事李挺拟斥200万元至400万元实施增持
泰恩康最新公告:董事李挺拟200万元—400万元增持公司股份
证券之星 · 04-23
泰恩康最新公告:董事李挺拟200万元—400万元增持公司股份
加载更多
公司概况
公司名称:
广东泰恩康医药股份有限公司
所属行业:
批发业
上市日期:
2022-03-29
主营业务:
广东泰恩康医药股份有限公司主营业务为代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品包括处方药、OTC、医疗器械、卫生材料、医药技术服务等。
发行价格:
19.93
{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":14.13,"timestamp":1716534231000,"preClose":14.12,"halted":0,"volume":1651940,"delay":0,"floatShares":268000000,"shares":425000000,"eps":0.3612,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"05-24 15:00:00","open":14.14,"high":14.3,"low":14.06,"amount":23367400,"amplitude":0.017,"askPrice":14.13,"askSize":102,"bidPrice":14.12,"bidSize":1562,"shortable":0,"etf":0,"ttmEps":0.3612,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716773400000},"adr":0,"adjPreClose":14.12,"symbolType":"stock","openAndCloseTimeList":[[1716514200000,1716521400000],[1716526800000,1716534000000]],"highLimit":15.53,"lowLimit":12.71,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":425497500,"pbRate":3.27,"roa":"--","roe":"2.51%","epsLYR":0.38,"committee":0.560263,"marketValue":6012000000,"floatMarketCap":3782000000,"peRate":39.119601,"changeRate":0.0007,"turnoverRate":0.0062,"status":0},"requestUrl":"/m/hq/s/301263","defaultTab":"news","newsList":[{"id":"2437897496","title":"泰恩康最新公告:全资子公司获得枸橼酸西地那非口崩片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437897496","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2437897496?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:30","pubTimestamp":1716280219,"startTime":"0","endTime":"0","summary":"泰恩康公告,全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的枸橼酸西地那非口崩片《药品注册证书》。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052100026979.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2437689495","title":"泰恩康(301263.SZ)获得两项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437689495","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437689495?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:26","pubTimestamp":1716280019,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康 发布公告,公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的枸橼酸西地那非口崩片《药品注册证书》。枸橼酸西地那非口崩片为美国辉瑞公司开发的西地那非迭代剂型,2019年在中国批准进口。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123825.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435687805","title":"泰恩康(301263.SZ)拟10股派3元 于5月23日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2435687805","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435687805?lang=zh_cn&edition=full","pubTime":"2024-05-15 17:46","pubTimestamp":1715766373,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康(301263.SZ)公告,公司2023年年度权益分派拟:向全体股东每10股派发现金红利3元(含税)。除权除息日为:2024年5月23日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121560.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434054833","title":"泰恩康(301263.SZ):利多卡因丙胺卡因气雾剂药品注册临床试验获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2434054833","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434054833?lang=zh_cn&edition=full","pubTime":"2024-05-10 17:40","pubTimestamp":1715334011,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康(301263.SZ)公告,公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的境内生产药品注册临床试验《受理通知书》,药品名称为:利多卡因丙胺卡因气雾剂。公告称,利多卡因丙胺卡因气雾剂是一种局部麻醉药物,主要用于治疗成年男性原发性早泄问题,临床疗效明确,使用方便。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119865.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434683532","title":"泰恩康最新公告:全资子公司利多卡因丙胺卡因气雾剂收到药品注册临床试验受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2434683532","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434683532?lang=zh_cn&edition=full","pubTime":"2024-05-10 17:39","pubTimestamp":1715333988,"startTime":"0","endTime":"0","summary":"泰恩康公告,全资子公司利多卡因丙胺卡因气雾剂收到药品注册临床试验受理通知书。利多卡因丙胺卡因气雾剂是一种局部麻醉药物,主要用于治疗成年男性原发性早泄问题,临床疗效明确,使用方便。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000034591.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433717115","title":"华安证券:给予泰恩康买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433717115","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433717115?lang=zh_cn&edition=full","pubTime":"2024-05-08 17:09","pubTimestamp":1715159395,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,李昌幸近期对泰恩康进行研究并发布了研究报告《主营业务稳健发展,CKBA创新药临床进展顺利》,本报告对泰恩康给出买入评级,当前股价为14.79元。未来CKBA有望成为公司的另一重磅品种。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有1家机构给出评级,买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800031005.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431722399","title":"泰恩康4月30日现1笔大宗交易 成交金额4218万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431722399","media":"智能小浪","top":-1,"share":"https://www.laohu8.com/m/news/2431722399?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:00","pubTimestamp":1714467600,"startTime":"0","endTime":"0","summary":" 4月30日,泰恩康平收,收盘价为14.28元,发生1笔大宗交易,合计成交量300万股,成交金额4218万元。 进一步统计,近3个月内该股累计发生5笔大宗交易,合计成交金额为1.27亿元。该股近5个交易日累计上涨8.10%,主力资金合计净流出153.95万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-04-30/doc-inatrchx0540021.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-04-30/doc-inatrchx0540021.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431395881","title":"4月30日泰恩康现4218万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2431395881","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431395881?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:41","pubTimestamp":1714466491,"startTime":"0","endTime":"0","summary":"证券之星消息,4月30日泰恩康发生大宗交易,交易数据如下:大宗交易成交价格14.06元,相对当日收盘价折价1.54%,成交300万股,成交金额4218万元,买方营业部为国泰君安证券股份有限公司汕头金砂路证券营业部,卖方营业部为华泰证券股份有限公司深圳深南大道基金大厦证券营业部。近三个月该股共发生5笔大宗交易,合计成交9.35万手,折价成交5笔。截至2024年4月30日收盘,泰恩康报收于14.28元,上涨0.0%,换手率1.21%,成交量3.25万手,成交额4675.02万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000034737.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430270884","title":"泰恩康(301263.SZ):甲巯咪唑片境内生产药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2430270884","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430270884?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:41","pubTimestamp":1714138867,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康 公告,公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的甲巯咪唑片境内生产药品注册上市许可申请《受理通知书》。另外,甲巯咪唑片还可用于甲状腺功能亢进症患者在使用放射性碘治疗前的准备用药,可以用于预防治疗后患者发生甲状腺毒性危象。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112433.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430291298","title":"泰恩康上市次年营收净利齐降 医药代理板块贡献过半营收财报提示风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2430291298","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2430291298?lang=zh_cn&edition=full","pubTime":"2024-04-26 10:31","pubTimestamp":1714098660,"startTime":"0","endTime":"0","summary":"中国网财经4月26日讯 泰恩康上市次年业绩滑坡。日前,泰恩康发布2023年报。泰恩康最早由医药代理起家,经过多年发展,医药代理板块仍是公司收入和利润的主要来源。2023年,医药代理板块实现营收4.3亿元,在营收中的占比超过50%。对此,泰恩康在年报中也提示了代理业务的风险,尤其是公司作为沃丽汀在中国的唯一总代理,如果代理关系中止或终止,将对公司的经营产生重大不利影响。近1年,泰恩康的股价已下跌近30%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-26/doc-inatcmza6917993.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-26/doc-inatcmza6917993.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430288658","title":"泰恩康:4月24日高管李挺增持股份合计5.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430288658","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430288658?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:01","pubTimestamp":1714050089,"startTime":"0","endTime":"0","summary":"证券之星消息,根据4月25日市场公开信息、上市公司公告及交易所披露数据整理,泰恩康最新董监高及相关人员股份变动情况:2024年4月24日公司董秘,董事,高管李挺共增持公司股份5.55万股,占公司总股本为0.013%。泰恩康近半年内的董监高及核心技术人员增减持详情如下:泰恩康的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入260.44万,融资余额增加;融券净流出5100.0,融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500044209.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429438130","title":"泰恩康:4月23日高管李挺增持股份合计10.87万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429438130","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429438130?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:01","pubTimestamp":1713952877,"startTime":"0","endTime":"0","summary":"证券之星消息,根据4月24日市场公开信息、上市公司公告及交易所披露数据整理,泰恩康最新董监高及相关人员股份变动情况:2024年4月23日公司董事会秘书,董事,副总经理李挺共增持公司股份10.87万股,占公司总股本为0.0255%。泰恩康近半年内的董监高及核心技术人员增减持详情如下:泰恩康的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入99.07万,融资余额增加;融券净流入600.0,融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400037954.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429612236","title":"【机构调研记录】金元顺安基金调研贝达药业、泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2429612236","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429612236?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916973,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,金元顺安基金近期对2家上市公司进行了调研,相关名单如下:1)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。2)泰恩康 个股亮点:?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013968.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429122580","title":"【机构调研记录】湘财基金调研泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2429122580","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429122580?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916963,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,湘财基金近期对1家上市公司进行了调研,相关名单如下:1)泰恩康 个股亮点:?公司主营产品包括一次性使用医用口罩。旗下最近一年表现最佳的基金产品为湘财久丰3个月定开债A,最新单位净值为1.06,近一年增长5.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013943.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429125707","title":"泰恩康(301263)2024年一季报简析:净利润减12.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429125707","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429125707?lang=zh_cn&edition=full","pubTime":"2024-04-24 06:23","pubTimestamp":1713911024,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期泰恩康发布2024年一季报。根据财报显示,本报告期中泰恩康净利润减12.54%。截至本报告期末,公司营业总收入1.89亿元,同比下降2.41%,归母净利润4546.78万元,同比下降12.54%。重仓泰恩康的前十大基金见下表:持有泰恩康最多的基金为宝盈核心优势混合A,目前规模为8.52亿元,最新净值0.6678,较上一交易日上涨0.45%,近一年下跌29.75%。今年一季度受整个海运周期、节假日的影响,进口量下降导致收入同比有所下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400012321.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429190978","title":"泰恩康:泰信基金管理有限公司、兴业基金管理有限公司等多家机构于4月23日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2429190978","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429190978?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:34","pubTimestamp":1713879244,"startTime":"0","endTime":"0","summary":"今年一季度受整个海运周期、节假日的影响,进口量下降导致收入同比有所下降。今年第一季度沃丽汀的销售收入相较于前一年同期呈现较积极增长。虽然目前尚未取得米诺地尔的批文,但公司已将其视为高度契合自身优势的品种,并计划在获得批件后,充分利用线上平台、连锁药店渠道以及品牌推广优势进行运营。公司对下半年实现司美格鲁肽产品的销售持乐观态度,主要是考虑到原研市场对该产品有较大的需求量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300041971.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429193370","title":"泰恩康(301263.SZ)董事李挺拟斥200万元至400万元实施增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429193370","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429193370?lang=zh_cn&edition=full","pubTime":"2024-04-23 19:24","pubTimestamp":1713871440,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康(301263.SZ)公告,公司董事、董事会秘书、副总经理李挺于2024年4月23日以集中竞价交易方式增持公司股份10.87万股,增持成交总金额为143.46万元。公司董事、董事会秘书、副总经理李挺拟自增持计划公告披露之日起3个月内通过深圳证券交易所交易系统以集中竞价的方式增持公司股份,拟增持金额不低于200万元且不超过400万元(含本次增持金额)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107802.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429198750","title":"泰恩康最新公告:董事李挺拟200万元—400万元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2429198750","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429198750?lang=zh_cn&edition=full","pubTime":"2024-04-23 19:19","pubTimestamp":1713871196,"startTime":"0","endTime":"0","summary":"泰恩康公告,公司董事、董事会秘书、副总经理李挺于4月23日以集中竞价交易方式增持公司股份10.87万股,成交总金额143.46万元。李挺拟继续增持公司股份,拟增持金额不低于200万元且不超过400万元(含本次增持金额),增持计划不设置增持股份价格区间。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300037413.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","stockEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0644},{"period":"3month","weight":0.0185},{"period":"6month","weight":-0.2145},{"period":"1year","weight":-0.311},{"period":"ytd","weight":-0.1168}],"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","perCapita":"21774股","boardName":"批发业","registeredCapital":"42549万元","compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":0.0145},{"period":"3month","weight":0.028},{"period":"6month","weight":0.0158},{"period":"1year","weight":-0.0351},{"period":"ytd","weight":0.0383}],"survey":" 广东泰恩康医药股份有限公司主营业务为代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品包括处方药、OTC、医疗器械、卫生材料、医药技术服务等。","serverTime":1716638571563,"listedPrice":19.93,"stockholders":"12294人(较上一季度减少4.56%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}